WEBULL
WebtradeDownload

Scholar Rock Holding (SRRK) Won FDA Approval, Is The Stock Still Trading At A Discount?

Simply Wall St · 2d ago

Scholar Rock Holding (SRRK) just received FDA approval for ISEMBYLD, a muscle targeted therapy for spinal muscular atrophy patients already on SMN2 treatments. This has prompted a special call that puts fresh attention on the stock.

Scholar Rock Holding’s share price has cooled after the FDA decision, with the stock down 12% over the past week and about 10% over the last month. However, a 15% year to date share price gain and a roughly 51% 1 year total shareholder return show momentum is still positive in a broader sense as investors weigh new growth potential against higher perceived risk.

Spot 16 high quality undiscovered gems in rare disease and specialty biotech that, like Scholar Rock Holding, sit at the crossroads of clinical milestones and shifting investor expectations.

Scholar Rock Holding just cleared a major regulatory hurdle, yet the share price has slipped on the news. Does that recent pullback offer a cleaner entry today, or does it argue for patience while the valuation case settles?

Most Popular Narrative: 21% Undervalued

Scholar Rock Holding last closed at $49.02 versus a most followed fair value estimate of $62.06. This frames the ISEMBYLD launch and wider neuromuscular pipeline as the main drivers of the valuation story.

Regulatory progress around apitegromab, including preparation for BLA resubmission in the U.S. and an ongoing MAA review in Europe, could support a transition from a development stage profile to a revenue generating commercial business, with direct implications for future revenue and earnings.

See why 1 investors see Scholar Rock Holding as 21% undervalued.

Result: Fair Value of $62.06 (UNDERVALUED)

Still, the story hinges on successful apitegromab execution and clean regulatory follow through. Any delay in approvals or slower uptake could quickly challenge the current Scholar Rock Holding narrative.

Find out about the key risks to this Scholar Rock Holding narrative.

Next Steps

Mixed messages in the Scholar Rock Holding story so far. Take a closer look at the tension between upside and downside, starting with the 3 key rewards and 3 important warning signs.

Looking For More Investment Ideas Beyond Scholar Rock Holding?

If you like what the Scholar Rock Holding story reveals about risk, reward, and timing, broaden your watchlist now with fresh opportunities that match your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.